Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature

References

• Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17.
   PubMed Web of Science ®Google Scholar
• Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12.
   PubMed Web of Science ®Google Scholar
• Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1–2):89–95.
   PubMed Web of Science ®Google Scholar
• Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e135.
   PubMed Web of Science ®Google Scholar
• Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951–959.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777–2786.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Rojhirunsakool S, Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34(9):1857–1864.
   PubMed Web of Science ®Google Scholar
• Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79(3):703–706.
   PubMed Web of Science ®Google Scholar
• Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–463.
   PubMed Web of Science ®Google Scholar
• Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759–776.
   PubMed Web of Science ®Google Scholar
• Sheikh S, Ahmad A, Ali SM, et al. A new topical formulation of minoxidil and finasteride improves hair growth in men with androgenetic alopecia. J Clin Exp Dermatol Res. 2015;6:1000253.
   Google Scholar
• Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–849.
   PubMed Web of Science ®Google Scholar
• Caserini M, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.
   PubMed Web of Science ®Google Scholar
• Mazzarella GF, Loconsole GF, Cammisa GA, et al. Topical finasteride in the treatment of androgenetic alopecia: preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8(3):189–192.
   Web of Science ®Google Scholar
• Sitticharoenchai P. Clinical evaluation of topical formulation of finasteride in male androgenetic alopecia [dissertation]. Bangkok: Chulalongkorn University; 2006.
   Google Scholar
• Khan MZU, Khan SA, Ubaid M, et al. Finasteride topical delivery systems for androgenetic alopecia. Curr Drug Deliv. 2018;15(8):1100–1111.
   PubMed Web of Science ®Google Scholar
• Roque LV, Dias IS, Cruz N, et al. Design of finasteride-loaded nanoparticles for potential treatment of alopecia. Skin Pharmacol Physiol. 2017;30(4):197–204.
   PubMed Web of Science ®Google Scholar
• Caon T, Porto LC, Granada A, et al. Chitosan-decorated polystyrene-b-poly(acrylic acid) polymersomes as novel carriers for topical delivery of finasteride. Eur J Pharm Sci. 2014;52:165–172.
   PubMed Web of Science ®Google Scholar
• Monti D, Tampucci S, Burgalassi S, et al. Topical formulations containing finasteride. Part I: in vitro permeation/penetration study and in vivo pharmacokinetics in hairless rat. J Pharm Sci. 2014;103(8):2307–2314.
   PubMed Web of Science ®Google Scholar
• Tabbakhian M, Tavakoli N, Jaafari MR, et al. Enhancement of follicular delivery of finasteride by liposomes and niosomes. 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm. 2006;323(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Madheswaran T, Baskaran R, Yong CS, et al. Enhanced topical delivery of finasteride using glyceryl monooleate-based liquid crystalline nanoparticles stabilized by cremophor surfactants. AAPS PharmSciTech. 2014;15(1):44–51.
   PubMed Web of Science ®Google Scholar
• Rao Y, Zheng F, Zhang X, et al. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech. 2008;9(3):860–865.
   PubMed Web of Science ®Google Scholar
• Limpongsa E, Jaipakdee N, Pongjanyakul T. Skin deposition and permeation of finasteride in vitro: effects of propylene glycol, ethanol and sodium lauryl sulfate. Pharm Dev Technol. 2014;20:1–8.
   Web of Science ®Google Scholar
• Charuwichitratana S, Krisdapong P, Sumethiwit R, et al. Randomized double-blind placebo controlled trial in the treatment of male androgenetic alopecia with 0.1% finasteride solution. Jpn J Dermatol. 2003;113:881.
   Google Scholar
• Hajheydari Z, Akbari J, Saeedi M, et al. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47–51.
   PubMed Web of Science ®Google Scholar
• Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312–1316.
   PubMedGoogle Scholar
• Chandrashekar BS, Nandhini T, Vasanth V, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17–20.
   PubMedGoogle Scholar
• Narasimhalu C. A cross-sectional randomized comparative study of topical minoxidil solution with and without finasteride in male pattern androgenetic alopecia in South Indian patients. Int J Res Dermatol. 2018;4(1):46–49.
   Google Scholar
• Rai PB, Khushwaha P, Jain N, et al. Comparing the therapeutic efficacy of topical minoxidil and finasteride with topical minoxidil and oral finasteride in androgenetic alopecia: a randomized trial. Int J Res Dermatol. 2018;4(3):386–390.
   Google Scholar
• Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153.
   PubMed Web of Science ®Google Scholar
• Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62–65.
   PubMedGoogle Scholar